Indivior Pharmaceuticals, Inc.
INDVHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeIndivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and. With a market capitalization of $4.07B, it sits in mid-cap territory. It develops medicines to treat substance use disorders.
Market Cap
$4.07B
Beta
1.18
P/E (TTM)
12.35
P/E (Fwd)
7.06
EPS (TTM)
$2.79
EPS (Fwd)
$4.88
ROE
—
ROA
26.4%
Cash
$222.0M
Total Debt
$509.0M
Free CF
$86.5M
52W Change
39.1%
Annual Financials
Cash vs Debt
Where INDV stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, INDV finished 10.63% below its 150-day moving average ($36.31) and 9.08% below its 200-day moving average ($35.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INDV overbought or oversold?
At the October 19, 2026 close, INDV's RSI(14) was 19.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, INDV has $222.0M in cash with $509.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $86.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 26.4% further supports the picture of efficient asset utilization. Revenue has grown from $901.0M (2022) to $1.24B (2025), reflecting a 38% increase over the period.
Investors considering Indivior Pharmaceuticals, Inc. should weigh the typical risks associated with INDV's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INDV.